Theravance Biopharma Net Cash Flow 2012-2025 | TBPH

Theravance Biopharma net cash flow from 2012 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Theravance Biopharma Net Cash Flow 2012-2025 | TBPH

Theravance Biopharma net cash flow from 2012 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.3B
Zoetis (ZTS)$67.7B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$46.1B
BeOne Medicines - (ONC)$31.9B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$21.3B
Merck (MKKGY)$17.2B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.7B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.9B
Stevanato Group S.p.A (STVN)$8B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B